Skip to main content

Table 2 Changes in estimated glomerular filtration rate (eGFR), CD4+ T cell count (CD4), and lipids at 24 and 48 weeks after starting darunavir/cobicistat

From: Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

  Dual therapy Triple therapy P between groups
Mean SD Mean SD
eGFR mL/min
 T0 94.2 20.3 96.3 23.6  
 T1 90.2 19.0 88.7 21.7  
 T2 86.7 17.7 87.7 18.6  
T1-T0 (mean, SE) − 4.6* 1.8 − 7.6* 1.3 0.19
T2-T0 (mean, SE) − 7.6* 1.9 − 8.5* 1.4 0.71
CD4 cells/mm3
 T0 625.2 381.0 580.6 342.9  
 T1 653.3 309.2 641.0 364.4  
 T2 712.6 326.0 664.1 365.0  
T1-T0 (mean, SE) 18.5 30.5 60.8* 15.6 0.22
T2-T0 (mean, SE) 35.3 26.7 64.2* 19.1 0.38
HDL mg/dL
 T0 51.0 16.6 47.0 14.8  
 T1 50.2 15.6 47.9 14.8  
 T2 52.8 16.3 47.3 15.2  
T1-T0 (mean, SE) − 1.2 1.0 1.2 0.8 0.07
T2-T0 (mean, SE) 1.8 2.2 0.7 1.2 0.62
TC mg/dL
 T0 200.0 47.6 187.3 42.5  
 T1 199.4 45.8 190.0 40.8  
 T2 204.5 45.3 192.5 46.6  
T1-T0 (mean, SE) − 1.2 3.6 3.6 2.3 0.24
T2-T0 (mean, SE) 0.1 5.0 2.4 3.3 0.69
TG mg/dL
 T0 (median, IQR) 128 92–169 124 88–168  
 T1 (median, IQR) 133 97–177 111 86–167  
 T2 (median, IQR) 145 90–183 120 86–194  
T1-T0 (mean, SE) 32.3 31.7 − 5.7 4.4 0.24
T2-T0 (mean, SE) 4.3 8.6 3.3 6.5 0.92
TC/HDL
 T0 4.20 1.34 4.27 1.37  
 T1 4.26 1.39 4.25 1.38  
 T2 4.11 1.21 4.31 1.29  
T1-T0 (mean, SE) 0.07 0.08 − 0.05 0.08 0.31
T2-T0 (mean, SE) − 0.13 0.14 − 0.05 0.09 0.62
  1. SD: Standard deviation; SE: standard error; T0: baseline; T1: 24 week follow up; T2: 48 week follow up; TC: total cholesterol, TG: triglycerides; HDL: HDL cholesterol
  2. * P for change from baseline < 0.05